Writing for Health: A randomised controlled trial of an online benefit-finding writing intervention for adults with type 1 or type 2 diabetes

Not Applicable

Completed

• Conditions: Type 1 and Type 2 diabetes mellitus; Diabetes distress; Diabetes self-care; Depression; Anxiety; Mental Health - Other mental health disorders; Public Health - Other public health; Metabolic and Endocrine - Diabetes

• Registration Number: ACTRN12615000241538
• Lead Sponsor: Faces in the Street: Urban Mental Health Research Institute, St Vincent’s Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-03-17
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 104

Inclusion Criteria

Participants must be aged 18 years or older, have ever received a diagnosis of type 1 or type 2 diabetes, live in Australia, have access to the Internet, provide informed consent and be able to register online using an email address.

Exclusion Criteria

Have received a diagnosis of a psychotic or bipolar disorder or dementia; current significant symptoms of depression (scoring 10 or above on the PHQ-9) or anxiety (scoring 8 or above on the GAD-7); current suicidal ideation; history of self-harm or suicide attempt; current psychological therapy; difficulty reading or writing in English; inability to type for 15 minutes

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Diabetes distress as measured by the Diabetes Distress Scale. The Diabetes Distress Scale is a 17-item self-report measure of psychosocial stress associated with diabetes and includes four reliable subscales: emotional burden, physician-related distress, regime-related distress and interpersonal distress.[Baseline, 1 month and 3 month follow-up.];Benefit finding in diabetes, as measured by the Benefit Finding Scale-Diabetes. The 17-item Benefit Finding Scale was developed to assess benefit finding in women with breast cancer, and has previously been adapted for use in diabetes. [Baseline, 1 month and 3 month follow-up.]